Will nirsevimab be the holy grail for prevention of respiratory syncytial virus lower respiratory tract infections in infants?
- PMID: 38590379
- PMCID: PMC10998989
- DOI: 10.21037/tp-23-534
Will nirsevimab be the holy grail for prevention of respiratory syncytial virus lower respiratory tract infections in infants?
Keywords: Respiratory syncytial virus (RSV); infants; monoclonal antibody; nirsevimab; respiratory syncytial virus prophylaxis (RSV prophylaxis).
Conflict of interest statement
Conflicts of Interest: The author has completed the ICMJE uniform disclosure form (available at https://tp.amegroups.com/article/view/10.21037/tp-23-534/coif). The author reports that she has received payment from Pfizer to write an educational piece on RSV for Australian College of Midwives, taken part as invited speaker for Sanofi, received support from Sanofi for meeting registration, accommodation and/or travel expenses, taken part in an Advisory board for MSD, and is a Chief investigator on an investigator-initiated grant investigating RSV complications in children funded by MSD, all outside of the present manuscript. The author has no other conflicts of interest to declare.
Comment on
-
Efficacy of nirsevimab against respiratory syncytial virus lower respiratory tract infections in preterm and term infants, and pharmacokinetic extrapolation to infants with congenital heart disease and chronic lung disease: a pooled analysis of randomised controlled trials.Lancet Child Adolesc Health. 2023 Mar;7(3):180-189. doi: 10.1016/S2352-4642(22)00321-2. Epub 2023 Jan 9. Lancet Child Adolesc Health. 2023. PMID: 36634694 Free PMC article.
References
-
- Shi T, McAllister DA, O'Brien KL, et al. Global, regional, and national disease burden estimates of acute lower respiratory infections due to respiratory syncytial virus in young children in 2015: a systematic review and modelling study. Lancet 2017;390:946-58. 10.1016/S0140-6736(17)30938-8 - DOI - PMC - PubMed
Publication types
LinkOut - more resources
Full Text Sources